Antineoplastic Agents, Phytogenic
"Antineoplastic Agents, Phytogenic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
Concept/Terms
Antineoplastic Agents, Phytogenic- Antineoplastic Agents, Phytogenic
- Agents, Phytogenic Antineoplastic
- Phytogenic Antineoplastic Agents
- Antineoplastics, Phytogenic
- Phytogenic Antineoplastics
- Antineoplastics, Botanical
- Botanical Antineoplastics
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Phytogenic".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Phytogenic".
This graph shows the total number of publications written about "Antineoplastic Agents, Phytogenic" by people in Harvard Catalyst Profiles by year, and whether "Antineoplastic Agents, Phytogenic" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 1 | 1 | 2 |
| 1995 | 5 | 0 | 5 |
| 1996 | 10 | 4 | 14 |
| 1997 | 8 | 5 | 13 |
| 1998 | 12 | 3 | 15 |
| 1999 | 14 | 4 | 18 |
| 2000 | 11 | 5 | 16 |
| 2001 | 10 | 5 | 15 |
| 2002 | 12 | 8 | 20 |
| 2003 | 9 | 4 | 13 |
| 2004 | 12 | 6 | 18 |
| 2005 | 21 | 8 | 29 |
| 2006 | 14 | 8 | 22 |
| 2007 | 8 | 5 | 13 |
| 2008 | 14 | 7 | 21 |
| 2009 | 5 | 9 | 14 |
| 2010 | 10 | 8 | 18 |
| 2011 | 12 | 11 | 23 |
| 2012 | 17 | 7 | 24 |
| 2013 | 13 | 12 | 25 |
| 2014 | 11 | 7 | 18 |
| 2015 | 17 | 8 | 25 |
| 2016 | 17 | 11 | 28 |
| 2017 | 8 | 2 | 10 |
| 2018 | 8 | 6 | 14 |
| 2019 | 6 | 4 | 10 |
| 2020 | 5 | 2 | 7 |
Below are the most recent publications written about "Antineoplastic Agents, Phytogenic" by people in Profiles.
-
Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients =65 years old: An ACC PVI Registry Analysis. Am Heart J. 2021 03; 233:59-67.
-
Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer. JAMA Netw Open. 2020 11 02; 3(11):e2027074.
-
Early Progression and Immune Reconstitution Inflammatory Syndrome During Treatment of Mild-To-Moderate Kaposi Sarcoma in Sub-Saharan Africa and South America: Incidence, Long-Term Outcomes, and Effects of Early Chemotherapy. J Acquir Immune Defic Syndr. 2020 08 01; 84(4):422-429.
-
Piperine suppresses the Wnt/ß-catenin pathway and has anti-cancer effects on colorectal cancer cells. Sci Rep. 2020 07 15; 10(1):11681.
-
Enhanced absorption, and efficacy of oral self-assembled paclitaxel nanocochleates in multi-drug resistant colon cancer. Int J Pharm. 2020 Aug 30; 586:119482.
-
Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. Lancet. 2020 04 11; 395(10231):1195-1207.
-
Extracting the benefits of berberine for colorectal cancer. Lancet Gastroenterol Hepatol. 2020 03; 5(3):231-233.
-
Gomisin A ameliorates metastatic melanoma by inhibiting AMPK and ERK/JNK-mediated cell survival and metastatic phenotypes. Phytomedicine. 2020 Mar; 68:153147.
-
Total Biosynthesis for Milligram-Scale Production of Etoposide Intermediates in a Plant Chassis. J Am Chem Soc. 2019 12 11; 141(49):19231-19235.
-
Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems. Exp Neurol. 2020 02; 324:113121.